The meta-analysis demonstrates that incidence of myalgia is not statistically different between PCSK9 inhibitor-treated groups and control groups and, therefore, it is not likely that PCSK9 inhibitors will induce myalgia any more than conventional treatment. The gene discussed is PCSK9; the disease is Myalgia.